Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DEX PS DDS · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| DEX PS DDS® | DRUG | - |
Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician. Exclusion: Females who are pregnant or lactating, and females of childbearing p...
DEX PS DDS is an investigational small molecule developed by AbbVie Inc. (ticker ABBV). It has been studied in a Phase 2 clinical trial in patients with persistent macular edema, a condition that can occur with diabetes, diabetic retinopathy, retinal disease, and posterior uveitis.
DEX PS DDS has been studied for persistent macular edema, a complication associated with diabetes, diabetic retinopathy, retinal disease, and posterior uveitis. The Phase 2 trial enrolled patients with these conditions. It is not approved for any indication and remains investigational.
DEX PS DDS is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company responsible for the asset's clinical development.
DEX PS DDS is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA for any indication.
DEX PS DDS has been evaluated in one completed Phase 2 trial, NCT00035906, titled Research Study in Patients With Persistent Macular Edema. The trial enrolled 315 patients in the United States, included patients aged 12 years and older, and was randomized but uncontrolled.
Yes, DEX PS DDS and DEX PS DDS® refer to the same investigational asset. The registered trademark symbol is simply a stylized version of the name used by the developer, AbbVie Inc. (ticker ABBV).